Clausena Harmandiana root extract attenuated cognitive impairments via reducing amyloid accumulation and neuroinflammation in Aβ 1-42 -induced rats.
Autor: | Nillert N; Department of Anatomy, Faculty of Medicine, Khon Kaen University, Khon Kaen, 40002, Thailand., Boonyarat C; Faculty of Pharmaceutical Sciences, Khon Kaen University, Khon Kaen, 40002, Thailand., Welbat JU; Department of Anatomy, Faculty of Medicine, Khon Kaen University, Khon Kaen, 40002, Thailand., Bunreungthong K; Department of Anatomy, Faculty of Medicine, Khon Kaen University, Khon Kaen, 40002, Thailand., Puthongking P; Faculty of Pharmaceutical Sciences, Khon Kaen University, Khon Kaen, 40002, Thailand., Pannangrong W; Department of Anatomy, Faculty of Medicine, Khon Kaen University, Khon Kaen, 40002, Thailand. wankun@kku.ac.th. |
---|---|
Jazyk: | angličtina |
Zdroj: | BMC complementary medicine and therapies [BMC Complement Med Ther] 2022 Apr 19; Vol. 22 (1), pp. 108. Date of Electronic Publication: 2022 Apr 19. |
DOI: | 10.1186/s12906-022-03591-4 |
Abstrakt: | Background: Alzheimer's disease (AD) pathogenesis is associated with amyloid-β (Aβ)-induced neuroinflammation. In AD, the activation of microglia caused by Aβ accumulation is followed by the synthesis and release of pro-inflammatory cytokines, including interleukin-1β (IL-1β) and tumor necrosis factor-α (TNFα), and ultimately leads to cognitive impairments. Clausena harmandiana (CH) is a medicinal plant in the Rutaceae family and has been used in folk medicine to relieve illnesses such as stomachache and headache, and as a health tonic. Interestingly, CH root extract (CHRE) has several anti-inflammatory and other pharmacological activities, but there are no studies in AD-like animal models. Objectives: This study aims to evaluate the effects of CHRE on cognitive impairments, increased Aβ Methods: Forty-eight adult male Sprague-Dawley rats (250-300 g) were randomly divided into 6 groups (n = 8) of the sham control, V + Aβ, CB + Aβ CHRE125 + Aβ, CHRE250 + Aβ, and CHRE500 + Aβ. Sodium carboxymethylcellulose, Celebrex (10 mg/kg BW) and CHRE (125, 250, and 500 mg/kg BW) were given orally or without any treatment for 35 days. On day 21, aggregated Aβ Results: Pretreatment with CHRE at all doses could attenuate short- and long-term impairments in recognition memory. Additionally, CHRE also inhibited the increase of Aβ Conclusions: This suggests that preventive treatment of CHRE might be a potential therapy against cognitive impairments via reducing Aβ (© 2022. The Author(s).) |
Databáze: | MEDLINE |
Externí odkaz: |